Figure 6.

The LB-100 and adavosertib combination restrains tumor growth in vivo. A, Endpoint tumor volumes of 3 independent orthotopic colorectal cancer PDXs treated with LB-100, adavosertib, or the combination for 4 weeks. After transplantation and engraftment, the mice were randomized and treated as indicated. LB-100 was given on days 1, 3, and 5, whereas adavosertib was administered on days 1–5 in 7-day cycles. Asterisks indicate significance level (*, P <0.05; **, P<0.01) by two-tailed Mann–Whitney test. B,Representative tumors and hematoxylin and eosin stainings at endpoint from PDOX1 treated as indicated. Original magnification middle images: 15×, scale bar, 1,000 μm; right images: 200×. Nindicates necrotic areas, S indicates stroma, and the arrows point to the tumor-cell component. C,Tumor growth curves of cholangiocarcinoma PDX1 treated with LB-100, adavosertib, or the combination. After transplantation and engraftment, the mice were randomized and treated as indicated. LB-100 was given on day 1, adavosertib was given on days 1–3, in 4-day cycles. Tumors were measured 3 times per week. Graphs, mean and SEM. Asterisks indicate significance level (****, P<0.0001) by two-way ANOVA with Tukey multiple comparisons. D,Body weight variation of the CCA PDX1 across the experiment. Graphs, mean and SEM; PDOX, patient-derived orthotopic xenograft.